Goals and priorities for potential HAE treatment, deucrictibant, announced by pharmaceutical company
The pharmaceutical company driving the development of a potential new medicine for HAE, deucrictibant, has announced their priorities for 2026. The following is a summary of these:
- Topline data from CHAPTER-3, a pivotal study of deucrictibant for prophylactic treatment of HAE attacks, anticipated in 3Q2026
- Preparation of NDA dossier of deucrictibant for on-demand treatment of HAE attacks ongoing; timeline remains on-track for filing in 1H2026
- Recruitment ongoing in CREAATE, a pivotal study of deucrictibant for the prophylactic and on-demand treatment of acquired angioedema (AAE-C1INH) attacks
Berndt Modig, Chief Executive Officer of Pharvaris said: “The readout of Pharvaris’ first pivotal Phase 3 study, RAPIDe-3, in December was the culmination of a decade of scientific rigor, operational and financial diligence, executional excellence, and, most importantly, community engagement and commitment. The data reported in December build upon Pharvaris’ legacy in HAE drug development, and we believe demonstrate deucrictibant’s potentially differentiated profile and potential to become a new standard of care for on-demand HAE treatment of attacks.”
(Source: Pharvaris)